Natera, Inc. (NASDAQ:NTRA) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC increased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 18,607.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 119,916 shares of the medical research company's stock after buying an additional 119,275 shares during the period. GAMMA Investing LLC owned about 0.09% of Natera worth $16,957,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Natera by 7.7% during the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP increased its holdings in Natera by 15.7% in the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after buying an additional 439,778 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Natera by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after buying an additional 142,201 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Performance

Natera stock traded down $1.75 during midday trading on Friday, hitting $163.76. 1,016,903 shares of the company's stock were exchanged, compared to its average volume of 1,407,598. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market cap of $22.36 billion, a price-to-earnings ratio of -93.05 and a beta of 1.74. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The firm's 50 day simple moving average is $151.77 and its 200 day simple moving average is $158.67.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business's revenue was up 36.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.56) earnings per share. Equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 1,026 shares of Natera stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $149,837.04. Following the sale, the insider now owns 144,782 shares of the company's stock, valued at approximately $21,143,963.28. The trade was a 0.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 6,111 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.10, for a total value of $960,038.10. Following the transaction, the chief executive officer now owns 179,071 shares in the company, valued at $28,132,054.10. The trade was a 3.30% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,275 shares of company stock valued at $10,075,783. Company insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent analyst reports. UBS Group lifted their price target on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Barclays boosted their target price on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Royal Bank of Canada assumed coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target for the company. BTIG Research reissued a "buy" rating on shares of Natera in a report on Friday, February 28th. Finally, Robert W. Baird boosted their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.